G, S., C, T., F, S., E, G., L, C., M, M., . . . F, B. (2024). The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. British journal of haematology, 204(1), 191. https://doi.org/10.1111/bjh.19218
Chicago Style (17th ed.) CitationG, Sartori, et al. "The ATR Inhibitor Elimusertib Exhibits Anti-lymphoma Activity and Synergizes with the PI3K Inhibitor Copanlisib." British Journal of Haematology 204, no. 1 (2024): 191. https://doi.org/10.1111/bjh.19218.
MLA (9th ed.) CitationG, Sartori, et al. "The ATR Inhibitor Elimusertib Exhibits Anti-lymphoma Activity and Synergizes with the PI3K Inhibitor Copanlisib." British Journal of Haematology, vol. 204, no. 1, 2024, p. 191, https://doi.org/10.1111/bjh.19218.
Warning: These citations may not always be 100% accurate.
